Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$462.88 USD

462.88
710,709

-0.27 (-0.06%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $462.85 -0.03 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Moderna (MRNA) Q1 Loss Narrows, Revenues Miss Estimates

Moderna (MRNA) reports narrower-than-expected first-quarter loss. The company plans to initiate phase II study on coronavirus vaccine soon.

Zacks.com featured highlights include: Logitech International, MACOM Technology Solutions, Murphy USA, Vertex Pharmaceuticals and The Clorox Company

Zacks.com featured highlights include: Logitech International, MACOM Technology Solutions, Murphy USA, Vertex Pharmaceuticals and The Clorox Company

Tirthankar Chakraborty headshot

4 Best Stocks to Buy for Stellar Earnings Growth

We have selected four solid stocks that have striking earnings growth and positive estimate revisions.

Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates

Horizon Therapeutics (HZNP) beat on earnings and sales in the first quarter of 2020. The company lifts net sales guidance for the full year.

Zacks.com featured highlights include: Activision Blizzard, Guardant Health, Vertex Pharmaceuticals, Aphria and Shopify

Zacks.com featured highlights include: Activision Blizzard, Guardant Health, Vertex Pharmaceuticals, Aphria and Shopify

Nilanjan Choudhury headshot

5 Stocks That Look Appealing on Relative Price Strength

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

James Giaquinto headshot

3 Market-Beating Growth Stocks

3 Market-Beating Growth Stocks

Can Vertex (VRTX) Run Higher on Rising Earnings Estimates?

Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks.com featured highlights include: Vertex Pharmaceuticals, Alibaba, Amedisys and Fabrinet

Zacks.com featured highlights include: Vertex Pharmaceuticals, Alibaba, Amedisys and Fabrinet

Zacks.com featured highlights include: Cogent Communications, Murphy USA, Vertex Pharmaceuticals and B2Gold

Zacks.com featured highlights include: Cogent Communications, Murphy USA, Vertex Pharmaceuticals and B2Gold

Sanghamitra Saha headshot

5 Top-Ranked Stocks to Tap Earnings Beat Potential

Forget earnings growth, bet on these top-ranked stocks to cash in on earnings beat.

Sumit Singh headshot

Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio

Interest Coverage Ratio suggests how many times the interest could be paid from earnings and gauges the margin of safety a firm has for paying interest.

Nitish Marwah headshot

4 Momentum Picks Screened on Driehaus Strategy

Driehaus strategy is perfect for investors who have the propensity to take high levels of risk.

Vertex (VRTX) Q1 Earnings Beat, Trikafta Drives CF Revenues

Vertex (VRTX) rides high on earnings and revenue beat in Q1.The company raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.

BioMarin (BMRN) Beats on Q1 Earnings, Lowers Sales View

BioMarin (BMRN) beats estimates for both earnings and sales in the first quarter. It lowers its total revenue outlook for the year due to the potential impact of coronavirus outbreak.

Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Beat Estimates

Vertex (VRTX) delivered earnings and revenue surprises of 39.89% and 19.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Sprouts Farmers Market, The Hain Celestial, Virtu Financial and Pixelworks

The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Sprouts Farmers Market, The Hain Celestial, Virtu Financial and Pixelworks

Here is Why Growth Investors Should Buy Vertex (VRTX) Now

Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Will Strong HIV Sales Drive Gilead's (GILD) Q1 Earnings?

Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on the experimental coronavirus treatment when Gilead (GILD) reports first-quarter 2020 results.

Why Vertex Pharmaceuticals (VRTX) Might Surprise This Earnings Season

Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Nalak Das headshot

5 Top-Ranked Nasdaq Stocks to Buy Ahead of Earnings Results

Despite the coronavirus-induced economic disaster and stock market turmoil, a handful of Nasdaq stocks are set to beat earnings estimates.

Why Vertex (VRTX) Could Beat Earnings Estimates Again

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

John Blank headshot

Big Tech Calls the Tune: Global Week Ahead

The S&P 500 earnings season hits a high note. What keys get struck the hardest? Q1 earnings reports due from five tech mega-caps.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for April 27th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Focus on Coronavirus Treatments to Boost Biotech Stocks

With the coronavirus pandemic raging on, biotech companies are in focus as they are racing against time to evaluate every possible therapy to combat the spread.